Valeant Pharmaceuticals International will pay $54 million to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products, causing the submission of thousands of fraudulent reimbursement claims to the U.S. government.
The accord announced on Thursday by the U.S. Department of Justice covers alleged improper activity at the former Salix Pharmaceuticals from 2009 to 2013, predating its April 2015 acquisition by Valeant VRX 5.10% for more than $11 billion.